SARS-CoV-2 variants are escaping neutralizing antibody responses, but have not escaped the T-cell response – A Johnson & Johnson Case Study
To understand immune evasion of emerging variants and vaccine responses, researchers need to go beyond the antibody response and study the T-cell immune response to SARS-CoV-2. T cells generate immune responses to various regions of the SARS-CoV-2 virus, providing a more comprehensive understanding of the immune response in COVID-19.
In this webinar, Dr. Harlan Robins, CSO & Co-founder, Adaptive Biotechnologies, will discuss a peer-reviewed study published in Nature, which used the immunoSEQ® T-MAP™ COVID technology to measure the T-cell immune response, induced by the Ad26.COV2.S COVID-19 vaccine, and quantify T-cell expansion across all regions of the SARS-CoV-2 virus, including the spike protein.
What you will learn
- Key findings and observations from the Nature study:
- Neutralizing antibody responses elicited by Ad26.COV2.S were reduced against the B.1.351 & P.1 variants, while CD4+ and CD8+ T cell responses and functional non-neutralizing antibody responses were largely preserved against the SARS-CoV-2 variants of concern;
- TCRβ sequencing with the immunoSEQ Assay revealed substantial breadth of T cell responses in Ad26.COV2.S vaccinated samples;
- Increase in spike-specific T-cell breadth and depth were observed. Breadth of non-Spike TCRs was comparable in vaccine recipients and controls, as expected since the vaccine did not contain any non-Spike immunogens;
- Understand how researchers used immunoSEQ® and immunoSEQ T-MAP COVID to understand, study, and map the vaccine-elicited T-cell immune response to SARS-CoV-2.
For Research Use Only. Not for use in diagnostic procedures.
Harlan Robins, PhD
Register for SEQdiscovery
To access this video and all SEQdiscovery content.
If you have previously registered and opted to have an account please log in above.